Xadago

Active Ingredient(s): Safinamide
FDA Approved: * March 21, 2017
Pharm Company: * NEWRON PHARMS US INC
Category: Parkinsons

Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.[2][3][4] It was approved in Europe in February 2015,[2] in the United States in March 2017,[3] and in Canada in January 2019.[5] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Overd... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Xadago 50 mg Oral Tablet, Film Coated
NDC: 27505-110
Labeler:
Us Worldmeds, LLC
Xadago 100 mg Oral Tablet, Film Coated
NDC: 27505-111
Labeler:
Us Worldmeds, LLC
Safinamide Mesylate
NDC: 68621-0030
Labeler:
Catalent Germany Schorndorf Gmbh
Xadago 100 mg Oral Tablet, Film Coated
NDC: 68621-0031
Labeler:
Catalent Germany Schorndorf Gmbh